A01K 2217/075
Inducing loss of function, i.e. knock out
Official title: inducing loss of function, i.e. knock out
A01K2217/075 (Inducing loss of function, i.e. knock out) appears on 2,141 US grants and 4,292 published applications in this corpus.
Search patents in A01K- Granted patents
- 2,141
- Published applications
- 4,292
- Assignees
- 1,289
- Inventors
- 6,674
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 19 | 0 |
| 1997 | 25 | 0 |
| 1998 | 52 | 0 |
| 1999 | 81 | 0 |
| 2000 | 93 | 0 |
| 2001 | 95 | 18 |
| 2002 | 89 | 246 |
| 2003 | 86 | 811 |
| 2004 | 87 | 250 |
| 2005 | 61 | 219 |
| 2006 | 102 | 241 |
| 2007 | 117 | 153 |
| 2008 | 131 | 134 |
| 2009 | 85 | 149 |
| 2010 | 82 | 138 |
| 2011 | 61 | 124 |
| 2012 | 57 | 95 |
| 2013 | 55 | 81 |
| 2014 | 60 | 79 |
| 2015 | 47 | 91 |
| 2016 | 44 | 88 |
| 2017 | 47 | 80 |
| 2018 | 55 | 86 |
| 2019 | 42 | 137 |
| 2020 | 50 | 147 |
| 2021 | 63 | 162 |
| 2022 | 58 | 186 |
| 2023 | 80 | 171 |
| 2024 | 68 | 158 |
| 2025 | 85 | 153 |
| 2026 | 58 | 95 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Rat models for CMT2A that develop a progressive neuropathy1 Sep 2026US 12,721,327 B2Charcot-Marie-Tooth Association
- Methods of treating mitochondrial disorders1 Sep 2026US 12,723,062 B2The Regents of the University of California
- Neurodegenerative and amyotrophic model animal25 Aug 2026US 12,714,076 B2Tokyo Metropolitan Institute of Medical Science
- Fullerenes to treat diseases and conditions25 Aug 2026US 12,714,679 B2The Cleveland Clinic Foundation
- KIR 7.1 gene therapy vectors and methods of using the same18 Aug 2026US 12,709,760 B2Wisconsin Alumni Research Foundation
- Neurogenesis17 Sep 2026US 2026/0272970 A1Brown University
- Cerebral microbleed animal model and preparation method therefor10 Sep 2026US 2026/0262614 A1Ajou University Industry-Academic Cooperation Foundation
- Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof3 Sep 2026US 2026/0256896 A1University of Washington through its Center for Commercialization
- Genetically modified animal-derived animal fiber27 Aug 2026US 2026/0248114 A1Setsurotech Inc.
- Method for knocking out bovine fbxo40 gene and application thereof27 Aug 2026US 2026/0248115 A1Beijing Forestry University
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Method of making transgenic mice lacking endogenous heavy chains1,057US 5,939,598 AAbgenix, Inc. · 1999
- Human antibodies derived from immunized xenomice1,057US 6,075,181 AAbgenix, Inc. · 2000